Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

HGH 191AA peptide iconHGH 191AA191 residues (approx.)FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

HGH 191AA

Beginner tier: 200 mcg, daily · community consensus

Growth HormoneFDA Approved
~2-4 hours half-life·Injection

Also known as: HGH, rHGH, somatropin

One IU of somatropin costs anywhere from $4 on the gray market to $60 at a brand-name pharmacy. HGH 191AA is the full 191-amino-acid recombinant human growth hormone, identical to what the pituitary gland produces. Multiple FDA-approved brand versions exist (Norditropin, Genotropin, Omnitrope), though most community users source compounded or research-grade product. The Norditropin label starts adults with GHD at 0.45 to 0.9 IU a day. AACE 2019 guidelines start at 0.3 to 1.5 IU, depending on age and health. Community anti-aging and body recomposition protocols push 2 to 4 IU daily, well above clinical dosing. Sleep and recovery improvements show up in the first two weeks; visible fat loss takes six to ten weeks of consistent use.

What Is HGH 191AA?

Sleep gets deeper within days. That's the first thing most users notice after starting HGH 191AA, the full-length 191-amino-acid recombinant human growth hormone (somatropin, CAS 12629-01-5). The compound is bioidentical to endogenous GH produced by the anterior pituitary.

Unlike secretagogues such as ipamorelin or CJC-1295 that signal the pituitary to release stored GH, exogenous somatropin bypasses the signaling chain entirely. Each injection delivers a known quantity of growth hormone directly into circulation. Subcutaneous bioavailability runs about 70 to 80 percent on US labels, and serum levels peak about 4 to 6 hours after the injection. The terminal half-life after a subcutaneous dose is 2 to 4 hours [1].

The FDA has approved multiple somatropin brands for adult growth hormone deficiency (GHD). Norditropin's current label (July 2025) starts adults at about 0.2 mg a day, within a 0.15 to 0.3 mg range. The dose then rises by 0.1 to 0.2 mg every 1 to 2 months, guided by response and IGF-1. Community protocols run considerably higher. Across r/PEDs, bodybuilding forums, and anti-aging communities, 2 to 4 IU per day (667 to 1333 mcg) is the standard body-recomposition dose, with advanced users pushing 4 to 6 IU.

Real-world results track a predictable pattern: sleep improvement in weeks 1 to 2, recovery gains by week 3, visible fat loss by weeks 6 to 10, and peak body composition changes at weeks 9 to 16. Insulin resistance is the main metabolic risk above 2 IU per day. Fasting glucose can rise 10 to 20 mg/dL, making regular blood work non-optional at any dose.

How HGH 191AA Works

Somatropin binds the growth hormone receptor (GHR), a type I cytokine receptor found on hepatocytes, adipocytes, myocytes, and chondrocytes. Receptor dimerization activates the JAK2-STAT5 signaling cascade. This triggers transcription of IGF-1 in the liver, which mediates most of the downstream anabolic and metabolic effects.

The lipolytic pathway is direct and GH-receptor-dependent. GH activates hormone-sensitive lipase in adipose tissue, breaking down stored triglycerides into free fatty acids. This is why morning fasted dosing is popular in community protocols; it amplifies the fat-mobilizing window before carbohydrate intake blunts the effect.

GH also stimulates chondrocyte proliferation and collagen synthesis in connective tissue. Bone mineral density moves more slowly. In the Genotropin label's adult trials, it dipped after 6 months of treatment and was back at baseline by 12 months. Protein synthesis in skeletal muscle increases through both direct GHR activation and IGF-1-mediated mTOR pathway signaling.

The negative feedback loop matters. Exogenous GH suppresses hypothalamic GHRH secretion and upregulates somatostatin release. This blunts endogenous pulsatile GH output during use; periodic off-cycles allow the hypothalamic-pituitary axis to recover its natural rhythm.

HGH 191AA Benefits

  • HGH 191AA benefits center on direct, dose-dependent growth hormone elevation with predictable outcomes.
  • Fat loss becomes visible around the midsection by weeks 6 to 10. In two 6-month Norditropin label trials in adults with GHD, total body fat fell about 4 to 5 percentage points more than on placebo.
  • Sleep depth improves within the first week. Community reports across thousands of user logs on r/PEDs consistently describe faster onset and longer deep-sleep phases, especially with pre-bed dosing.
  • Skin elasticity and hydration measurably improve by weeks 8 to 12, a finding corroborated in both GHD replacement studies and anti-aging community use.
  • Workout recovery shortens noticeably by weeks 3 to 4. Users report returning to training faster and with less soreness.
  • Connective tissue strengthens over longer cycles, as IGF-1-mediated collagen synthesis supports joint repair. Bone density moves more slowly. In the Genotropin label's adult trials, it dipped at 6 months and was back at baseline by 12.
  • Lean mass preservation during caloric deficit is one of the most valued effects in recomposition protocols; GH shifts fuel utilization toward fatty acid oxidation, sparing muscle protein.

HGH 191AA: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Strong
Based on 10 key studies·FDA-approved

Exogenous recombinant somatropin is the gold-standard, FDA-approved treatment for adult GHD with strong Phase 3 evidence.

Dosing studied: 0.15–0.3 mg/day start (0.45–0.9 IU/day), raised 0.1–0.2 mg every 1–2 months, for adult GHD (Norditropin label); up to 2 mg/day (6 IU/day) in off-label performance contexts
Read the evidence (key study, limitations)

Off-label body-composition and anti-aging use shows real but modest benefits in healthy adults. Performance-enhancement evidence is weak despite clear anabolic mechanism.

Key Study

Norditropin (somatropin) FDA Prescribing Information (July 2025); NCBI Bookshelf: Somatropin for Growth Hormone Deficiency (NBK596750); Frontiers Endocrinology: Titrating GH Dose to High-Normal IGF-1 (2020)

Limitations

High-quality RCTs cover diagnosed GHD populations almost exclusively. Healthy-adult body-composition trials are small and short-duration. Long-term safety of supraphysiological dosing (community 2–6 IU/day) is not formally studied. Cancer risk via sustained IGF-1 elevation is a real concern with chronic high-dose use.

Community Experience
Strong
3.5/5
Based on thousands of user logs across r/PEDs, r/Peptides, Anabolic Steroid Forums, and bodybuilding communities

Universally regarded as the most reliable and direct GH elevation method: preferred over secretagogues for predictability and potency.

Community dosing: 1–4 IU/day (333–1333 mcg/day) for most use cases; 4–8 IU/day reported in advanced bodybuilding
Read the reports (what users report 6, common issues 6)

Heavy use across anti-aging, body-recomposition, and competitive bodybuilding communities.

What users report (6)
  • Improved sleep depth and onset within 1–2 weeks
  • Visible visceral fat loss by weeks 6–10
  • Skin elasticity and hydration improvements
  • Faster workout recovery from week 3–4
  • Lean mass preservation during calorie deficit
  • Nail and hair growth acceleration
Common issues (6)
  • Water retention and bloating common in weeks 1–8
  • Carpal tunnel syndrome at doses ≥2 IU/day
  • Insulin resistance / fasting glucose elevation
  • High dimer content in gray-market products increases side effects
  • Cost: gray-market quality is highly variable
  • Injection site lipohypertrophy without proper rotation
Partially Aligned

Science firmly supports GHD-replacement dosing, which starts at 0.45–0.9 IU/day on the Norditropin label (0.3–1.5 IU/day by age in AACE 2019 guidelines). Community protocols routinely run 2–6 IU/day for body-composition purposes: about 3–10× the label's typical 0.6 IU starting dose. The anabolic mechanism is fully understood, but no high-quality RCTs exist in healthy adults at community-level doses. Real benefits are plausible and user-reported, but risk profile scales with dose.

HGH 191AA Dosage Guide

CommunitySomatropin: community dosing consensus
LevelDose / InjectionFrequency
Beginner200 mcg
DailyTrack
Moderate500 mcg
DailyTrack
Aggressive1 mg
DailyTrack
Note:

The IU-to-mcg conversion trips up most beginners: 1 IU equals roughly 333 mcg. A 10 IU vial holds about 3.3 mg of somatropin. A 15 IU vial holds roughly 5 mg.

Reconstitution math for the standard 10 IU vial: add 1 mL bacteriostatic water. That gives you 10 IU per mL. On a U-100 insulin syringe, 10 units equals 1 IU (333 mcg). For the beginner dose of 200 mcg (0.6 IU), draw 6 units. Moderate dose of 500 mcg (1.5 IU) is 15 units. Aggressive dose of 1000 mcg (3 IU) is 30 units.

Swirl the vial gently after adding water. Never shake or vortex somatropin; the protein is fragile and shaking creates dimers that increase side effects. Store reconstituted vials at 2 to 8 degrees Celsius and use within 14 to 28 days, depending on the product label. Lyophilized (powder) vials also belong in the fridge. Never freeze reconstituted HGH.

Morning fasted injection maximizes fat mobilization. Pre-bed injection amplifies the natural nocturnal GH pulse and tends to improve sleep quality. Split dosing (AM plus PM) is common at 3 IU per day or above.

Calculate your HGH 191AA dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

HGH 191AA Protocols by Goal

beginnerCommunity16–24 weeks; 4–8 week break with IGF-1 lab before resuming
Foundation
Wk 1–4
333 mcg (1 IU) · Daily · Subcutaneous
Maintenance
Wk 5–24
333–667 mcg (1–2 IU) · Daily · Subcutaneous

Expected: Improved sleep quality (2–4 wk), skin elasticity (8–12 wk), mild fat loss (12–24 wk)

Monitor: IGF-1 at baseline, week 4, week 8, and cycle end. Fasting glucose monthly.

How to Use HGH 191AA

  1. 1
    Step 1

    Gather supplies: one vial of lyophilized HGH 191AA, bacteriostatic water, a U-100 insulin syringe (29 or 31 gauge, 0.5 inch needle), and alcohol swabs.

  2. 2
    Step 2

    Clean the top of both the HGH vial and the bacteriostatic water vial with alcohol swabs. Let them air dry.

  3. 3
    Step 3

    Draw 1 mL (100 units on the syringe) of bacteriostatic water. For a 10 IU vial, this gives 10 IU per mL. For a 15 IU vial, this gives 15 IU per mL.

  4. 4
    Step 4

    Inject the water slowly down the inside wall of the HGH vial. Do not spray it directly onto the powder. Let gravity pull the water down; tilt the vial if needed.

  5. 5
    Swirl gently until the powder dissolves completely

    The solution should be clear. If it stays cloudy after five minutes, the product may be degraded. Do not use a cloudy solution.

  6. 6
    Draw your dose

    For a 10 IU vial reconstituted with 1 mL: beginner 200 mcg (0.6 IU) equals 6 units; moderate 500 mcg (1.5 IU) equals 15 units; aggressive 1000 mcg (3 IU) equals 30 units.

  7. 7
    Step 7

    Pinch a fold of skin on the abdomen (avoiding a 2-inch radius around the navel), thigh, or glute. Insert the needle at a 45 to 90 degree angle. Inject slowly. Rotate sites each injection.

  8. 8
    Timing depends on your goal

    Morning fasted for fat loss prioritization. Pre-bed for sleep quality and recovery. Split AM plus PM for doses above 3 IU per day.

  9. 9
    Step 9

    Store the reconstituted vial upright in the refrigerator at 2 to 8 degrees Celsius. Use within 14 to 28 days, depending on the product label. Do not freeze.

Alternative Routes

Subcutaneous (SC)

Reference route: no adjustment needed

Bioavailability ~70–80%. Slower absorption than IM but steady, sustained serum levels. Abdomen preferred; thigh and glute acceptable. Rotate injection sites systematically.

Intramuscular (IM)

No US label gives an IM dose; one study found higher exposure IM than SC (PMID 1490668)

Faster Tmax than SC (3 h vs 4 to 6 h) and higher total exposure (AUC 194 vs 134 ng·h/mL) in 12 healthy volunteers (PMID 1490668). More painful. Not standard in clinical or community settings. Occasionally used by bodybuilders for convenience.

Intravenous (IV)

100% bioavailability vs ~70–80% SC; dose may need downward adjustment

Used in PK studies and hospital GHD diagnostic testing. Not appropriate for home or community use. Risk of rapid GH surge and acute side effects.

Mixing your own vial? Use the HGH 191AA reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

HGH 191AA Stacking Protocols

Works With

Avoid

Exogenous insulin

Advanced bodybuilders combine insulin with HGH for extreme anabolism, but insulin + GH dramatically increases risk of life-threatening hypoglycemia. GH blunts insulin sensitivity (raising glucose), which can mask early hypoglycemic warning signs when exogenous insulin is co-administered. Not appropriate for beginners under any circumstances.

Do not combine
Somatostatin analogs (octreotide, lanreotide, pasireotide)

Somatostatin directly inhibits GH secretion and opposes HGH's GH-receptor activity downstream. Co-administration negates HGH efficacy. Clinically used intentionally to block GH in acromegaly.

Do not combine
Oral estrogen (OCP or oral HRT)

Oral estrogen reduces hepatic GH sensitivity and IGF-1 response significantly. May require 2× higher dose to achieve equivalent IGF-1 elevation. Transdermal estrogen has substantially less impact.

Chronic glucocorticoids (prednisone, dexamethasone)

Chronic glucocorticoid use reduces GH efficacy and may unmask adrenal insufficiency: GH can impair cortisol synthesis. Patients on long-term steroids using HGH need adrenal function monitoring.

Estimated Cost

Brand Price
Norditropin FlexPro (Novo Nordisk) / Genotropin (Pfizer): $1,200–$2,000/month retail at pharmacy for typical 2 IU/day dose; discounted cash price ~$900–$1,400/month. Omnitrope (Sandoz): discounted cash price ~$800–$1,200/month.
Compounded
No compounded price is listed: FDA says licensed biologics such as somatropin are not eligible for the 503A and 503B compounding exemptions (March 2020 notice)
Generic / Research
Gray-market research "HGH 191AA": ~$37–$44 per 10 IU vial; 150 IU kit ~$350–$380 (~$120–$140/month at 2 IU/day). Quality highly variable: see qualityRisk.

Pricing updated 2026-04-09

HGH 191AA Side Effects

Insulin resistance is the most clinically important risk with HGH 191AA. At doses of 2 IU per day or higher, fasting blood glucose can rise 10 to 20 mg/dL. The Norditropin FDA label lists new-onset type 2 diabetes and impaired glucose tolerance as labeled adverse events. Fasting glucose monitoring is mandatory, especially in the first eight weeks. If fasting glucose consistently reaches 100 mg/dL, dose reduction or discontinuation is warranted. HbA1c should be checked at baseline and every three to six months on-cycle to catch cumulative glucose dysregulation.

Carpal tunnel syndrome is fully dose-dependent. Numbness and tingling in the hands appear most often at 2 IU per day or above. The mechanism involves fluid retention in the carpal tunnel sheath compressing the median nerve. Symptoms typically resolve within two to four weeks after dose reduction. A wrist splint at night helps during acute episodes. Pushing through this symptom at higher doses risks nerve damage.

Water retention and peripheral edema are common during the first four to eight weeks. Hands, feet, and face are the most affected areas. Sodium restriction and pre-bed timing (instead of morning injection) can reduce severity. This side effect generally stabilizes as the body adapts, but it's the primary quality-of-life complaint in early weeks.

Supraphysiological IGF-1 is a real long-term concern. Chronically raised IGF-1 above age-normal ranges is associated with increased cancer risk and acromegalic changes (jaw thickening, extremity enlargement). IGF-1 labs are the single most important monitoring tool. Target the upper half of normal for age; avoid sustained levels above 350 ng/mL.

Gray-market quality introduces additional risks that pharmaceutical-grade product doesn't carry. High dimer content (improperly bonded GH molecules) increases side effects while reducing efficacy. Bacterial endotoxins from poor manufacturing can cause injection-site reactions, fever, and systemic inflammation. This is not a hypothetical concern; it's the most common source of disproportionate side effects reported in community forums.

Injection site lipohypertrophy (hardened lumps under the skin) develops when the same spot is used repeatedly. Rotating injection sites across abdomen quadrants, thighs, and glutes prevents this. Never inject the same location more than once per week.

Thyroid function can shift during use. GH increases peripheral conversion of T4 to T3, which may drop Free T4 levels and unmask subclinical hypothyroidism. Anyone on levothyroxine should get a thyroid panel at baseline and mid-cycle.

Intracranial hypertension is a label warning that's easy to miss. Headache, vision changes, nausea or vomiting can signal it, usually within the first 8 weeks. Labels call for an eye exam before starting and periodically after, and stopping if papilledema shows up.

US label contraindications: active malignancy, active proliferative or severe non-proliferative diabetic retinopathy, and acute critical illness after major surgery, trauma or respiratory failure. Also listed: children with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. Hypersensitivity to somatropin or its excipients is on the list, as is growth use in children whose epiphyses have closed. A past cancer isn't on that list, but labels require it to be inactive and fully treated first. Pregnancy isn't either; labels say the human data are too limited to judge the risk.

Common Issues & Solutions

Water retention / hand and foot edema: reduce dose by 0.5–1 IU/day; try pre-bed timing instead of AM injection; sodium restriction helps; typically improves after weeks 6–8 as body adapts.

Carpal tunnel (numbness/tingling in hands): fully dose-dependent: reduce by 0.5–1 IU/day; symptoms resolve in 2–4 weeks post-reduction; wrist splint at night relieves acute symptoms; do not push through this at higher doses.

Fasting glucose elevation / insulin resistance: lower dose or split AM + PM to reduce peak; avoid high-glycemic foods in the 2-hour post-injection window; if FBG consistently ≥ 100 mg/dL, reduce dose or discontinue.

IGF-1 above upper-normal range for age: mandatory dose reduction: supraphysiological IGF-1 is associated with cancer risk and acromegalic changes; target upper-normal, not maximum possible.

Injection site lipohypertrophy (lumps, hard spots): rotate injection sites systematically: abdomen quadrants, both thighs, glutes; never inject the same spot more than once per week.

Ask AI about this page

Ask AI for a second opinion on HGH 191AA dosing and side effects

Contraindications

  • Active malignancy: any past cancer must be inactive and its treatment complete before starting (US labels)
  • Proliferative or severe non-proliferative diabetic retinopathy
  • Acute critical illness due to surgery, trauma, or respiratory failure
  • Children with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
  • Known hypersensitivity to somatropin, excipients, or metacresol preservative
  • Closed epiphyses in children when used for linear growth: no further height benefit
  • Pregnancy or breastfeeding: not a label contraindication; labels say human data are too limited to judge the risk

Drug Interactions

  • Glucocorticoids: GH lowers cortisol activation (11β-HSD1) and can unmask adrenal insufficiency. Anyone on glucocorticoid replacement may need higher maintenance or stress doses; cortisone acetate and prednisone are affected most (US labels)
  • Insulin and oral hypoglycemics: GH raises blood glucose; diabetes medication doses may need adjustment
  • Thyroid hormones: GH can increase conversion of T4 to T3; monitor thyroid function and adjust levothyroxine if needed
  • CYP450-metabolized drugs (e.g., cyclosporine, sex steroids, anticonvulsants): GH may alter clearance of these medications
  • Estrogen (oral): oral estrogen reduces GH response; transdermal estrogen has less impact
  • Somatostatin analogs (octreotide, lanreotide, pasireotide): suppress GH secretion and are used to block GH in acromegaly, so they work against HGH (community stack guidance)

Product Quality

Recommended Monitoring

TestWhenTarget
IGF-1 (serum)Baseline; every 4 weeks during titration; every 6–12 weeks at maintenanceUpper half of normal range for age/sex: approximately 150–300 ng/mL for adults 30–60 years; avoid sustained levels > 350 ng/mL
Fasting blood glucoseBaseline; weekly for first 8 weeks; monthly thereafter< 100 mg/dL; investigate if consistently ≥ 100 mg/dL; discontinue if > 126 mg/dL
HbA1cBaseline; every 3–6 months on-cycle; at cycle end< 5.7% (pre-diabetic threshold)
Thyroid panel (TSH + Free T4)Baseline; every 6 monthsNot listed
Lipid panel (total cholesterol, LDL, HDL, triglycerides)Baseline; every 6 monthsNot listed
IGF-1 (serum)

Primary efficacy and safety biomarker: reflects integrated GH activity over days. Mandatory for dose titration. Supraphysiological IGF-1 is associated with cancer risk and acromegalic changes.

Fasting blood glucose

HGH causes clinically significant insulin resistance at doses ≥2 IU/day: fasting glucose can rise 10–20 mg/dL or more

HbA1c

Detects cumulative glucose dysregulation that spot fasting glucose alone may miss in longer cycles

Thyroid panel (TSH + Free T4)

GH increases peripheral T4-to-T3 conversion: Free T4 may fall, potentially unmasking subclinical hypothyroidism; adjust levothyroxine if on thyroid replacement

Lipid panel (total cholesterol, LDL, HDL, triglycerides)

GHD is associated with unfavorable lipid profiles; HGH replacement typically improves LDL/HDL ratio: labs confirm expected benefit and detect any adverse lipid changes

HGH 191AA Before and After

Weeks 1-2

Improved sleep depth and onset. Mild water retention and joint stiffness possible as the body adjusts. No visible body composition changes yet.

Weeks 3-4

Energy and recovery noticeably improved. Skin begins to feel smoother and more hydrated. Mild carpal tunnel symptoms may appear at higher doses.

Weeks 5-8

Fat loss becomes visible, especially around the midsection. Lean muscle fullness increases. Workout recovery time shortens. Nail and hair growth may accelerate.

Weeks 9-16

Peak body composition changes. Skin elasticity and tone markedly improved. Joint comfort often improves despite initial stiffness. IGF-1 levels stabilize at an elevated baseline.

Weeks 16-24+

Long-term benefits in connective tissue repair, bone density, and immune function. Results are dose-dependent. Periodic blood work (IGF-1, fasting glucose) is recommended.

What to Expect

Weeks 1 to 2: Sleep changes come first. Most users notice deeper sleep and faster onset within the first few days of dosing. Serum GH rises immediately with each injection, and IGF-1 starts climbing within the first week or two. Mild water retention in the hands and feet is normal at this stage. Joint stiffness can appear at higher starting doses. No visible body composition changes yet.

Weeks 3 to 4: Recovery is the next signal. IGF-1 approaches its steady-state level. Protein synthesis ramps up and lipolytic activity in fat tissue measurably increases. Workouts feel different because recovery times noticeably shorten. Skin starts to feel plumper and more hydrated. Carpal tunnel tingling may show up if you're running 2 IU per day or higher. Fasting glucose elevation becomes detectable on lab work.

Weeks 5 to 8: Fat loss becomes visible. Lipolysis accelerates and fat mass starts declining, typically starting around the midsection and flanks. Muscle fullness and vascularity improve. Workout performance and strength trend upward. Water retention usually peaks in this window and then stabilizes. Carpal tunnel tends to be at its worst here at higher doses.

Weeks 9 to 16: Peak body composition changes. The Norditropin label's trials measured body fat at 6 months, just past this window. Total body fat fell about 4 to 5 points more than on placebo. Skin elasticity and tone are markedly improved. Joints often feel better now despite the initial stiffness from earlier weeks. Nails and hair grow noticeably faster. Side effects generally diminish as the body adapts. Glucose management becomes the main monitoring priority.

Weeks 16 to 24 and beyond: Long-term connective tissue benefits accumulate. Bone density can dip first; in the Genotropin label's adult trials it fell by 6 months and returned to baseline by 12 months. Collagen synthesis continues, supporting joint and skin health. Body composition gains tend to plateau at a given dose. Diminishing returns past 24 weeks without a dose adjustment are common. Watch for any signs of acromegalic changes (jaw or brow thickening, hand or feet enlargement) with prolonged high-dose use.

Detailed Timeline: Science vs Community

Weeks 1–2
Science

Serum GH rises immediately with each dose. IGF-1 begins to elevate within 1–2 weeks. No measurable body composition changes at this stage.

Community

Better sleep depth and faster sleep onset: often within days. Mild water retention in hands and feet. Joint fullness or stiffness at higher doses.

Weeks 3–4
Science

IGF-1 approaches steady state. Protein synthesis upregulated. Lipolytic activity in adipose tissue measurably increased.

Community

Workout recovery noticeably faster. Skin begins to feel plumper and more hydrated. Carpal tunnel tingling may appear at doses ≥2 IU/day.

Weeks 5–8
Science

Adipose tissue lipolysis accelerates: fat mass begins to decline. Lean mass accretion starts. Metabolic rate increases.

Community

Visible fat loss: midsection and flanks first. Muscle fullness and vascularity improve. Workout performance and strength trend up.

Weeks 9–16
Science

Body fat falling (the Norditropin label's 6-month trials found total body fat 4–5 points lower than on placebo). Lean mass preservation or mild gain. IGF-1 stable at elevated baseline.

Community

Skin elasticity and tone markedly improved. Joint comfort often paradoxically improves despite initial stiffness. Nails and hair grow faster.

Weeks 16–24+
Science

Bone mineral density dipped at 6 months and was back at baseline by 12 months in the Genotropin label's adult trials. Connective tissue repair continues. Sustained IGF-1 elevation supports collagen synthesis.

Community

Body composition plateau at same dose: diminishing returns past 24 weeks without dose adjustment. Connective tissue, skin, and joint benefits continue accumulating.

Pharmacokinetics

Half-Life
3h
Bioavailability
SC: ~70-80% (US labels: Zomacton 70%, Humatrope 75%, Genotropin 80.5%); IV: 100% (reference)
Tmax
4-6 hours (SC)
Data Confidence
high

Source: SC terminal half-life of 2-4 hours in healthy volunteers (PMID 11505794); US labels give 2.3-3.8 hours

Pharmacokinetics: Active Dose Over Time

t½ = ~2-4 hours

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
191
Molecular Weight
22,124.8 Da
Sequence
FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEF
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 12629-01-5

Who Should Consider HGH 191AA

  • Adults with diagnosed growth hormone deficiency (GHD) seeking replacement therapy
  • Athletes and bodybuilders aiming for accelerated muscle growth and fat loss
  • Older adults experiencing age-related GH decline affecting sleep, skin, and recovery
  • Individuals recovering from surgery, injury, or burns requiring enhanced tissue repair
  • Adults seeking body recomposition with direct, predictable GH elevation

Related Peptides

What Changed for HGH 191AA

  1. Safety

    Corrected Oct 14, 2026: HGH side effects now list the label contraindications and the intracranial hypertension warning, per the Norditropin label.

    Before: Contraindications paragraph called cancer history and pregnancy or breastfeeding absolute stop signs; no intracranial hypertension warning After: Label contraindications listed in full; a past cancer must be inactive and treated first; pregnancy data too limited; intracranial hypertension warning added

    What this does not mean: No new risk. Past cancer and pregnancy stay on the page as label cautions; the labels contraindicate active malignancy and call pregnancy data too limited to judge.

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  2. Dosing

    Corrected Oct 14, 2026: HGH's adult GHD protocol now starts at 150 to 300 mcg a day, not 33 to 167 mcg, per the Norditropin label.

    What this does not mean: The old protocol read a 0.1 to 0.5 mg range as IU, a third of the intended dose. The calculator tiers (200, 500 and 1,000 mcg) are unchanged.

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  3. Safety

    Corrected Oct 14, 2026: HGH's glucocorticoid interaction now says replacement doses may need to rise, per the Norditropin label.

    Before: Glucocorticoids (prednisone, hydrocortisone) may reduce GH efficacy; somatostatin line said it opposes HGH's receptor activity After: GH inhibits 11β-HSD1 and can unmask adrenal insufficiency; anyone on glucocorticoid replacement may need higher maintenance or stress doses, cortisone acetate and prednisone most; somatostatin analogs work against HGH

    What this does not mean: No interaction was removed. The somatostatin analog line was reworded to fix a display error and drop an unsourced receptor claim.

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  4. Dosing

    Corrected Oct 14, 2026: HGH 191AA's summary, dosage FAQ and consensus note now give the adult GHD label start, 0.45 to 0.9 IU a day, per the Norditropin label.

    What this does not mean: The 0.3 to 1.5 IU range stays, labelled as AACE 2019 guideline starting doses by age. The calculator tiers (200, 500 and 1,000 mcg) are unchanged.

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

  5. Safety

    Corrected Oct 14, 2026: HGH contraindications now follow the label, with past cancer and pregnancy as cautions, per the Norditropin label.

    Before: Active malignancy or history of cancer; Prader-Willi syndrome with severe obesity or respiratory impairment; pregnancy or breastfeeding, each a contraindication After: Active malignancy (past cancer inactive and treated first); children with Prader-Willi syndrome at obesity, airway or breathing risk; pregnancy as a label caution

    What this does not mean: Both cautions stay listed. Active malignancy remains a contraindication, and a past cancer must be inactive and fully treated before starting.

    Source: Norditropin (somatropin) prescribing information (openFDA label record, SPL version 30, effective Jul 7, 2025) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Sep 24, 202613 Citations

References

  1. [1]Pharmacokinetics of human growth hormone administered subcutaneously with two different injection systems (Arzneimittelforschung 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]WHO International Standard for somatropin: 1 mg = 3 IU
  3. [3]Genotropin prescribing information (DailyMed, Aug 2026): reconstituted cartridge refrigerated up to 28 days
  4. [4]Zomacton prescribing information (DailyMed, Aug 2026): reconstituted 5 mg vial 14 days, 10 mg vial 28 days
  5. [5]The Use and Abuse of Growth Hormone in Sports (Holt and Ho, Endocr Rev 2019) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration (Cowan and Moncrieffe, Drug Test Anal 2022) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Further Reading

Storage & Stability

Before Reconstitution
Store at 2-8°C, stable 18-24 months sealed. Norditropin FlexPro pens: refrigerate unused; once in use, 4 weeks refrigerated or 3 weeks at room temperature (≤25°C)
After Reconstitution
Refrigerate at 2-8°C, use within 14 to 28 days depending on the product label. Do not freeze reconstituted solution.
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

The calculator uses community-consensus tiers of 200, 500, and 1000 mcg a day. At the WHO international standard of 3 IU per mg, that is about 0.6, 1.5, and 3 IU. Many community protocols run 1 to 4 IU a day. Clinical GHD treatment starts at 0.45 to 0.9 IU a day on the Norditropin label. AACE 2019 guidelines start at 0.3 to 1.5 IU, by age (PMID 31760824). Split doses above 3 IU into morning and afternoon injections to reduce side effects. Community experience consistently supports starting low and titrating up over 4-6 weeks.

Fluid retention leads. In a 6-month Norditropin label trial in adults with GHD, peripheral edema hit 42% vs 8% on placebo. The label calls these effects, carpal tunnel included, usually transient and dose dependent. Joint pain, morning stiffness, and numbness in hands typically appear in weeks 2-4 and often resolve with dose reduction. Insulin resistance is the main long-term concern; fasting glucose monitoring is recommended every 3 months on cycle.

Sleep improvement often appears within the first week. Skin quality and recovery benefits show up around weeks 4-6. Body composition changes (fat loss, muscle density) typically become measurable at 8-12 weeks. Full results require 4-6 months of consistent dosing.

HGH 191AA refers to the 191-amino-acid recombinant human growth hormone, which is the same sequence used in pharmaceutical brands like Norditropin, Genotropin, and Omnitrope. The difference is manufacturing quality. Pharmaceutical brands go through FDA-regulated production; gray-market 191AA varies widely in purity, with third-party testing showing 82-100% purity across brands.

Lyophilized (powder) vials stay stable at 2-8 degrees C for 18-24 months. Once reconstituted, refrigerate and use within 14 to 28 days, depending on the product label. The Genotropin label allows 28 days; the Zomacton 5 mg vial allows 14. Once in use, a Norditropin FlexPro pen keeps 4 weeks in the fridge or 3 weeks at room temperature (up to 25 degrees C). Never freeze reconstituted HGH.